Cadila and Pieris create drug development partnership MUMBAI -- Cadila Healthcare Ltd and German biopharmaceutical company Pieris AG have signed a research alliance to develop and sell multiple anticalin protein therapeutics, a new class of drugs that can be used for the treatment of a variety of disorder...
Oct. 17, 2013 - MedCity News
Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalin® Therapeutics Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin®-based protein therapeutics, both companies announced today.
Oct. 16, 2013 - Business Wire via Yahoo! Finance
Kristian Jensen in SYS-CON Media Kristian Jensen commented further: "Pieris has made remarkable progress over the past three years and together with its current financial strength, offers an exciting opportunity to further develop the Anticalin(R) portfolio, thereby combining...